Table 3.
A summary of the clinical course of the 16 patients with thyrotoxic periodic paralysis secondary to Graves' disease (TPP/GD).
| Patient number | Sex/age (years) | Primary treatment modality | Interval to first thyrotoxic relapse (months) | Treatment for first thyrotoxic relapse | Interval to second thyrotoxic relapse (months) | Treatment for second thyrotoxic relapse | Follow-up period (months) | Thyroid function status on latest follow-up |
|---|---|---|---|---|---|---|---|---|
| 1∗ | M/31 | ATD | 22 | ATD | 25 | Surgery | 68.0 | T4 |
| 2 | M/33 | ATD | 76# | ATD | 20 | ATD | 124.8 | Hyperthyroid |
| 3∗ | M/17 | ATD | 35# | ATD | 23† | ATD | 86.3 | Hyperthyroid |
| 4∗ | M/25 | ATD | 40 | ATD | 52 | Surgery | 113.7 | T4 |
| 5∗ | M/32 | ATD | 28 | RAI 250 MBq | 12 | RAI 250 MBq | 154.3 | T4 |
| 6 | M/23 | ATD | 247# | RAI 350 MBq | 6† | RAI 350 MBq | 293.2 | T4 |
| 7 | M/27 | ATD | 102# | RAI 250 MBq | 5† | RAI 300 MBq | 146.1 | T4 |
| 8∗ | M/24 | ATD | 29 | Surgery | — | — | 66.0 | T4 |
| 9∗ | M/33 | RAI 300 MBq | 29# | ATD | — | — | 87.3 | Euthyroid |
| 10∗ | M/23 | RAI 350 MBq | 12 | RAI 300 MBq | — | — | 49.7 | T4 |
| 11∗ | M/39 | RAI 300 MBq | — | — | — | — | 22.4 | Euthyroid |
| 12∗ | M/42 | RAI 350 MBq | — | — | — | — | 96.5 | T4 |
| 13∗ | M/45 | Surgery | — | — | — | — | 11.2 | T4 |
| 14∗ | F/26 | Surgery | — | — | — | — | 152.2 | T4 |
| 15∗ | M/32 | Surgery | — | — | — | — | 19.3 | T4 |
| 16 | M/39 | Surgery | — | — | — | — | 125.6 | T4 |
GD/TPP: thyrotoxic periodic paralysis secondary to Graves' disease; ATD: antithyroid drugs; RAI: 131I or radioactive iodine; T4: requiring daily thyroxine replacement.
Note: the primary treatment of patient 7 was switched to PTU due to allergy to CMZ.
*Where TPP was the first presenting symptom of thyrotoxicosis.
#Patient who had an attack of TPP during the first thyrotoxic relapse.
†Patient who had an attack of TPP during the second thyrotoxic relapse.